Cleveland BioLabs, Inc. (NASDAQ:CBLI)

CAPS Rating: 1 out of 5

The Company is engaged in the discovery, development and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins.

Results 1 - 20 of 23 : 1 2 Next »

Recs

1
Member Avatar zzlangerhans (99.83) Submitted: 6/26/2015 12:15:39 PM : Underperform Start Price: $6.81 CBLI Score: +40.50

It's frustrating to see a crappy low float nanobiotech liike Cleveland Biolabs jumping 150% in a session when everyone else's stocks are tanking. Those lucky bastards who bottom fed on that stock! How did they know? Well, a look at the five year chart shows that it's not so simple. https://finance.yahoo.com/echarts?s=CBLI+Interactive#{%22range%22:%225y%22,%22allowChartStacking%22:true}

Cleveland Biolabs stock has been dying a slow death since it traded at a split-adjusted 165 in April 2011. Back then the stock was flying high on false information coming from management and coordinated pumpers on Seeking Alpha. The claim was that a Department of Defense contract for radiation sickness protector CBLB502 was practically signed. That contract never materialized and the pumpers vanished, presumably with stuffed pockets. The share price continued to degrade, a process which was accelerated by a 20:1 reverse split in January. It would have been easy to pick Cleveland Biolabs as a bottom stock any time in 2014, and no doubt many tried. However, despite the massive gain yesterday only buyers since the beginning of 2015 are coming out ahead, and who knows how long that will last.

The impetus for yesterday's stock breakout was company PR that they had raised 25M via a private placement to Davidovich at 3.87, a 35% premium to the previous close. The stock far overshot the placement price due to the immediate assumption by the market that Davidovich must be aware of something the street was missing to explain the purchase at a premium. This presumption was no doubt juiced by the fact that the company has Russian partners and is running early phase trials in Russia.

There's very little information on Google about David Davidovich, aside from a Forbes profile and a page on a site calling itself "Russian mafia". Hm. He has been a close associate of top Russian oligarch Roman Abramovich. Many news reports about yesterday's deal describe him as a venture capital investor, yet a Google search for "David Davidovich venture capital" turns up no hits unrelated to Cleveland Biolabs. His Bloomberg Business profile turns up nothing except his ownership of a Russian meat processing company.

It looks like Davidovich is a black box, which brings me back to Cleveland Biolabs. Management claims to still be negotiating with the Department of Defense regarding 15M in funding, but they seem to be muting expectations with reminders that the deadline is September 30. A phase I trial of Entolimod (CBLB502) in advanced cancers is in progress in Russia. The company has completed a phase I trial of TLR 2,6 activator CBLB612 in healthy subjects and plans to continue development as a hematopoietic proliferative agent. They had almost no cash left when the recent financing was announced.

All these developments raise a couple of possibilities:

1. Davidovich knows something about Cleveland Biolabs' pipeline that the street doesn't know. Some miraculous response to Entolimod in Russian cancer subjects, for example. It seems unlikely because the company has run similar early stage trials in the US years ago. Davidovich is not a known biotech investor like Adage or Philip Frost or the Baker Brothers. He appears to be a complete unknown in the US stock market.

2. Shenanigans. Russian billionaires have been known to launder money through expensive art purchases and foreign real estate deals. Why not nanocap biotech companies? Also, we've seen how trading in these poorly overseen stubs can be extremely profitable for American slimebags. Why shouldn't the Russian mafia take a bite?

My experience over the last eight years has taught be that the skeptical view is generally the safer one, especially when it seems the big money has already been made and there are so many smarter trades available in the sector. Then again, you probably won't see me taking a short position either. I don't want to end up on a security cam video being shot down by four guys on motorcycles.

Recs

0
Member Avatar pchop12316 (34.23) Submitted: 6/26/2015 10:58:49 AM : Underperform Start Price: $5.78 CBLI Score: +30.65

let's get back tp reality

Recs

0
Member Avatar AndrewGreenBull (99.09) Submitted: 4/8/2014 10:53:31 AM : Outperform Start Price: $0.69 CBLI Score: +458.49

Should be back to $1 soon

Recs

0
Member Avatar turningpoint84 (82.11) Submitted: 7/22/2013 12:00:53 PM : Outperform Start Price: $1.67 CBLI Score: +113.94

I have a good feeling about them.

Recs

0
Member Avatar JULGABANN (47.88) Submitted: 4/9/2013 5:45:23 PM : Outperform Start Price: $1.60 CBLI Score: +109.60

Cleveland is way undervalued at this point, 2 drug applications for CBLB502 and a BARDA deal on the way... this will double in weeks and be a great buy and hold stock for years to come.

Recs

0
Member Avatar thecashmen (< 20) Submitted: 6/4/2012 4:03:33 PM : Underperform Start Price: $2.07 CBLI Score: -27.98

big pop big drop

Recs

0
Member Avatar SamsaricSufferer (55.47) Submitted: 4/8/2012 3:57:20 PM : Outperform Start Price: $1.56 CBLI Score: +102.10

Bounce coming. Recent news was not the death knell that was touted.

Recs

0
Member Avatar TMFBiologyFool (96.46) Submitted: 4/5/2012 1:24:45 PM : Outperform Start Price: $1.68 CBLI Score: +86.41

Overreaction to BARDA decision looks like a buying opportunity.

Recs

0
Member Avatar oznola (< 20) Submitted: 2/27/2012 10:00:26 PM : Outperform Start Price: $3.89 CBLI Score: -50.00

Price action indicates upward trend in monthly, weekly and daily time frame. Volume spike + Chaikin Oscillator indicates bullish trend.

Recs

0
Member Avatar dcsilver (63.81) Submitted: 12/29/2011 11:46:14 AM : Outperform Start Price: $2.76 CBLI Score: -22.21

Stock fell off in July. Since then, heavy insider purchases and a thumbs up from zzlangerhan.

Recs

0
Member Avatar Dynablob (21.51) Submitted: 3/5/2011 12:16:45 PM : Outperform Start Price: $7.05 CBLI Score: -100.35

Asymmetric risk/reward. BARDA grant would further legitimize science behind 502, leading to domestic & international government orders. Total market size should be $300-$500 million for the drug, and CBLI should get good margins on a large order.

Recs

0
Member Avatar 650driver (47.68) Submitted: 12/3/2010 1:22:32 PM : Outperform Start Price: $7.09 CBLI Score: -113.69

A golfing buddy of mine told me his son had recently bought 50,000 shares of a bioteck co and asked me to look at it for him. I rarely buy stocks under $ 10 and almost never one that dosn't pay at least a 4 % div.
I suggested to my buddie that his son should have a winner and if he could afford a little risk he should jump on it also. I then bouhgt 5000 shrs and several options.
Todays news granting "orphan status" from tha FDA intiated this post. If this drug comes anywhere near doing what their studies show, it couyld be a triple bagger very quickly. I bought between 6.00 and 6.30 it croosed 9.95 this am.

Recs

0
Member Avatar longterm90 (< 20) Submitted: 10/6/2010 8:58:57 AM : Outperform Start Price: $5.43 CBLI Score: -106.35

Won a DoD contract for $45 million. Lots of news out on this one in the past few weeks including a patent being granted.

Recs

1
Member Avatar Interpol10 (63.50) Submitted: 7/19/2010 9:23:14 PM : Outperform Start Price: $3.50 CBLI Score: -83.49

If all goes well with CBLI's research, we can hope to see a drug that increases human resistance to radiation. In my opinion, a truly groundbreaking discovery with an obtainable goal in sight, and their first round of testing going well only adds to my optimism.

Recs

0
Member Avatar diversified1 (83.51) Submitted: 10/29/2007 11:48:42 PM : Outperform Start Price: $12.60 CBLI Score: -110.45

Read the Bios of their researchers, you will be impressed. In this world the projects they are working on are timely and amazing.

Recs

0
Member Avatar sixfigsdn (< 20) Submitted: 9/18/2007 7:21:54 PM : Outperform Start Price: $12.00 CBLI Score: -109.59

Expecting 200M+ dod contract to develope ARS drug in October.

Recs

0
Member Avatar BigWhereItCounts (< 20) Submitted: 7/14/2007 8:22:56 PM : Underperform Start Price: $11.00 CBLI Score: +105.16

Way too high of price/sales and price/book

Recs

0
Member Avatar zaphelps (86.13) Submitted: 5/29/2007 11:11:28 AM : Outperform Start Price: $9.28 CBLI Score: -101.67

The company focuses on radiation drug discovery. The drugs they are working on target only cancer cells and don't harm normal tissues. Their inital target is to protect humans from radiation as a result of a terrorist attack or nuclear accident.

Recs

2
Member Avatar NetscribeServcs (< 20) Submitted: 3/21/2007 7:51:49 AM : Underperform Start Price: $8.90 CBLI Score: +111.25

Cleveland Biolabs (CBL) is a biotechnology research and development company, which develops drugs offering protection from radiation and cancer. CBL is engaged in the development of small molecule drugs and biologics focusing on two therapeutic directions, which includes development of drugs that protect normal tissues from the damaging effects of ionizing radiation and chemotherapy (protectans), and development of anti-cancer drugs for regulating cell death (curaxins).

Financially company has been running in losses from past three-four years. For the nine months ended in 2006, company’s revenues increased 93% to $1.5 million predominantly driven by increase in government grants. But it had a net loss totaled of $4.3 million, which was owing to an increase in selling, general and administrative expenses. Also due to creating and improving the infrastructure of the company and higher research & development expenses incurred for internal projects.

CBL intends to respond to a Request for Proposal (RFP) recently issued by the Department of Defense (DoD) for the Advanced Development of Medical Radiation Countermeasures to treat gastrointestinal effects of acute radiation syndrome. More recently company completed a $30 million private placement. This will provide them with two years of working capital and enable them to fulfill the requirements of the DoD's RFP as well as move forward with the development of radiation protection, cancer treatment and stem cell proliferation. But the above would gain only in the long run.

Looking at all the above factors and consequently due to increasing expenses in research & development every year coupled with deteriorating financials, the scrip is expected to enter a bearish phase.

Recs

0
Member Avatar hyronx (< 20) Submitted: 2/27/2007 6:31:08 PM : Outperform Start Price: $9.47 CBLI Score: -115.32

This stock went way up since New Year 2007 and made up to 150%

Results 1 - 20 of 23 : 1 2 Next »

Featured Broker Partners


Advertisement